4.92
+0.41%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Carvolix
Its shares trade on Euronext Paris under the ticker CVX.PA. It has been listed since 14 June 2021. In the fiscal year to 31 December 2024, it reported revenue of €4.1m and a net loss of €14.7m. At that date it held total assets of €60.9m and shareholders' equity of €30.3m.
Affluent Medical SA provides treatments for serious and widespread diseases. The company is headquartered in Aix-En-Provence, Paca. The company went IPO on 2021-06-14. The company designs minimally invasive prostheses at mimicking human anatomy and restoring native physiology for critical functions in cardiovascular and urological therapies. The company provides several products such as Kalios, Epygon, Artus. The company helps in treating heart disease and urinary incontinence. The firm provides transcatheter and flow control technologies, such as mimicry of anatomy and restoration of physiology minimally invasive implant procedures, optimized and biocompatible components.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 14 Jun 2021
- Employees
- 54
- Website
- affluentmedical.com ↗
Leadership
Pay as last reported
- Mr. Michel TherinChairman of the Board€38,000
- Mr. Sebastien LadetChief Executive Officer
- Mr. Christophe de VregilleChief Financial Officer
- Ms. Celine BuardMarketing Director
- Ms. Claire AndreDirector of Quality Assurance
- Ms. Federica AzzimontiDirector of Clinical Operations
- Mr. Olivier BellamyDirector of Industrialization
- Prof. Nicolas DelonchampsChief Medical Officer - Urology
- Dr. Howard HermannChief Medical Officer - Structural Heart
- Mr. Eric JagueDirector of Regulatory Affairs
- Prof. Francois LabordeChief Surgical Officer, since 2023
- Ms. Marion MelotArtus Program Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Carvolix designs minimally invasive prostheses mimicking human anatomy for cardiovascular therapies.
- The company employs 54 full-time staff members in Aix-en-Provence.
- Products like Kalios and Epygon treat heart disease and urinary incontinence.
Weaknesses
- The firm operates in Aix-en-Provence, which is not a major tech hub.
- Carvolix has only 54 employees, limiting its operational scale significantly.
- The company went public on 14 June 2021, making it relatively new.
Opportunities
- Carvolix can expand its transcatheter technologies into new urological therapy markets.
- The firm offers biocompatible components that appeal to modern medical standards.
- Restoring native physiology creates demand for innovative cardiovascular treatment solutions.
Threats
- Carvolix faces competition in the crowded cardiovascular therapy sector globally.
- Regulatory changes in France could impact the listing date of 2021.
- Economic downturns may reduce spending on elective urological procedures.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.